Plum Bio's 2016 net profit of 1 billion, proposed to be divided into 930 million

2016, Meihua Bio realized operating income of RMB11,092.772 million, a decrease of 6.42% compared with the same period a year earlier, and net profit attributable to shareholders of listed companies was RMB104,169 million, an increase of 144.84% compared with the same period in 2015XzY
Faced with the complex external macro environment and overcapacity, product prices of the industry status quo, the company's net profit growth is mainly due to the company's increase in production efficiency, the early layout of animal nutrition amino acid products brought about by incremental income, as well as the company hired an internationally renowned consulting firm McKinsey to review the procurement management process, the promotion and curing of sales strategyXzY
Net profit attributable to the owner of the parent company for the 2016 year was RMB1,041,689,943.85, plus undistributed profit of RMB2,730,531,360.03 for the year, net of the distributed profit of RMB310,8 Undistributed profit at the end of 2016 was RMB3,350,581,236.84 after taking out the surplus of $110,817,406.74XzY
At present, the company's cash flow is relatively abundant, the asset and liability structure is reasonable, and in 2017 there is no significant capital expenditure arrangement, in accordance with the provisions of the Articles of Association, in order to better return shareholders, the company's proposed profit distribution plan (plan) is: the total share capital of 3,108,226,603 shares as the base, to all shareholders for each 10 shares of the distribution of cash dividends of 3.00 yuan (including tax), the expected distribution of profit 932,467,90 00 yuan (tax)XzYoperating income of RMB11,109,277.2 million, a decrease of 6.42% compared to the same period a year earlier, and net profit attributable to shareholders of listed companies was RMB104,169 million, an increase of 144.84% over the same period in 2015XzY
Faced with the complex external macro environment and overcapacity, product prices of the industry status quo, the company's net profit growth is mainly due to the company's increase in production efficiency, the early layout of animal nutrition amino acid products brought about by incremental income, as well as the company hired an internationally renowned consulting firm McKinsey to review the procurement management process, the promotion and curing of sales strategyXzY
Net profit attributable to the owner of the parent company for the 2016 year was RMB1,041,689,943.85, plus undistributed profit of RMB2,730,531,360.03 for the year, net of the distributed profit of RMB310,8 Undistributed profit at the end of 2016 was RMB3,350,581,236.84 after taking out the surplus of $110,817,406.74XzY
At present, the company's cash flow is relatively abundant, the asset and liability structure is reasonable, and in 2017 there is no significant capital expenditure arrangement, in accordance with the provisions of the Articles of Association, in order to better return shareholders, the company's proposed profit distribution plan (plan) is: the total share capital of 3,108,226,603 shares as the base, to all shareholders for each 10 shares of the distribution of cash dividends of 3.00 yuan (including tax), the expected distribution of profit 932,467,90 00 yuan (tax)XzY